Abstract: An electronic device and a method of making an electronic device. As non-limiting examples, various aspects of this disclosure provide various methods of manufacturing electronic devices, and electronic devices manufactured thereby, that comprise utilizing an adhesive layer to attach an upper electronic package to a lower die and/or utilizing metal pillars for electrically connecting the upper electronic package to a lower substrate, wherein the metal pillars have a smaller height above the lower substrate than the lower die.

Abstract: A focusing method of a camera for obtaining an image of a surveillance area by performing a pan-tilt-zoom (PTZ) operation is included. The focusing method includes: determining whether a region of interest set in the surveillance area is included in a first image obtained by the camera; converting a mode according to a result of the determination by selecting a first mode in which focusing is performed using a first focusing algorithm or a second mode in which focusing is performed using a second focusing algorithm that is different from the first focusing algorithm; and focusing the camera with respect to the first image according to the first mode or the second mode.

Abstract: Provided are a polyamideimide film, a window cover film, and a display panel including the same. More specifically, a polyamideimide film including an amideimide structure derived from a dianhydride, a diamine, and an aromatic diacid dichloride is provided, wherein a chlorine content in the film is 5 to 33 ppm and a yellow index change amount ?YI is 5 or less, the yellow index change amount being measured in accordance with ASTM E313 after repeating a process of irradiating 0.55 W/m2 of UVA at 340 nm at 40° C. for 20 hours and then blocking UVA for 4 hours three times.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A coil component includes a body; first and second coil portions spaced apart from each other in the body; first and second external electrodes disposed on the body to be spaced apart from each other and connected to both ends of the first coil portion; and first and second ground electrodes spaced apart from each other on the body and connected to both ends of the second coil portion.

Abstract: A display panel can include a substrate, a light-emitting element including an emission region on the substrate, a reference voltage line adjacent to the light-emitting element, and a branch line connected to the reference voltage line to apply a reference voltage to light-emitting element. The light-emitting element can emit light on the emission region in a direction of the substrate. Further, the branch line can include a semiconductor layer, and the semiconductor layer of the branch line can overlap the emission region.

Abstract: An electronic device and a method of making an electronic device. As non-limiting examples, various aspects of this disclosure provide various methods of manufacturing electronic devices, and electronic devices manufactured thereby, that comprise utilizing an adhesive layer to attach an upper electronic package to a lower die and/or utilizing metal pillars for electrically connecting the upper electronic package to a lower substrate, wherein the metal pillars have a smaller height above the lower substrate than the lower die.

Abstract: A compound represented by Formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof may be used for treating or preventing an autoimmune disease or a cancer. The autoimmune disease may be any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, asthma, atopy, psoriasis, rheumatoid arthritis, systemic lupus erythematous and type 1 diabetes. The cancer may be selected from the group consisting of colon cancer, melanoma, liver cancer, gliocytoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, kidney cell cancer, stomach cancer, breast cancer, metastatic cancer, prostate cancer, gallbladder cancer, pancreatic cancer, blood cancer, skin cancer and lung cancer.

Abstract: The present invention relates to: a novel 4-methoxy-2-phenethyl isoindolin-1-one derivative compound having the ability to promote the increase of nerve growth factor, the ability to promote the growth of nerve cells, and antineuritic activity; and a composition for preventing, improving and treating neurological diseases, comprising the same.

Abstract: A compound represented by Formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof may be used for treating or preventing an autoimmune disease or a cancer. The autoimmune disease may be any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, asthma, atopy, psoriasis, rheumatoid arthritis, systemic lupus erythematous and type 1 diabetes. The cancer may be selected from the group consisting of colon cancer, melanoma, liver cancer, gliocytoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, kidney cell cancer, stomach cancer, breast cancer, metastatic cancer, prostate cancer, gallbladder cancer, pancreatic cancer, blood cancer, skin cancer and lung cancer.

Abstract: The present invention relates to: a novel 6-methoxy-2-phenethyl isoindolin-1-one derivative compound having the ability to promote the increase of nerve growth factor, the ability to promote the growth of nerve cells, and antineuritic activity; and a composition for preventing, improving and treating neurological diseases, comprising the same.

Abstract: The present invention relates to a cytokine trimer domain in which a first monomer and a second monomer linked by linker (dimer) and a third monomer are coupled by a knob-into-hole and a novel type of fusion protein in which antibody and cytokine trimer domains are linked (receptor-antibody conjugated (cell) engager, RACE) prepared by replacing a constant region (Fc) of an antibody with the cytokine trimer domain, and RACE according to the present invention exhibits superior binding ability to the target receptor than the parent antibody as well as excellent simultaneous binding ability to the antigen and the target receptor, which can be usefully utilized as a bispecific pharmaceutical composition.

Abstract: The present disclosure discloses a method and system for training a neural network for determining severity, and more particularly, a method and system which may effectively learn a neural network performing patch unit severity diagnosis using a pathological slide image to which a severity indication (label) is given.

Abstract: A drug injection control device includes a housing, a dose dial, a cartridge holder fixedly coupled to an opposite side of the housing, an injection button positioned in the dose dial, an injection amount setting module, and a drug delivery module, wherein the injection amount setting module includes a reset tube switchably coupled to the dose dial by the operation of the injection button, a ratchet tube coupled to an outer side of the reset tube to rotate at the same time, a scale drum which slidably rotates along an axial direction on an outer surface of the ratchet tube, a torsion spring having two ends coupled to the housing and the ratchet tube, and an anchor rotatably coupled to the ratchet tube and slidably coupled to an inside of the housing.

Abstract: Disclosed is a method for preparing a composition comprising factor VIII (FVIII) and von Willebrand factor (vWF), wherein the content of the von Willebrand factor (vWF) can be controlled by mixing the factor VIII (FVIII) with the von Willebrand factor (vWF) at an appropriate ratio after separately purifying the factor VIII (FVIII) and the von Willebrand factor (vWF) from plasma in a single process. The method can prepare and purify a composition comprising factor VIII (FVIII) and a varying content of von Willebrand factor (vWF) without increasing the amount of impurities other than the von Willebrand factor (vWF) compared to a method of purifying factor VIII (FVIII) separately, without significantly increasing the processing time (within 3 hours) compared to a method of purifying factor VIII (FVIII), and without changing the yield of factor VIII (FVIII).

Abstract: Disclosed are a coating composition for a composite positive electrode active material and a method of preparing a composite positive electrode active material using the same.

Abstract: A drug injection control device has a structure in which a rod lock screw-coupled to an outer circumferential surface of a piston rod can only make a linear motion under restricted rotation in a rod holder with the rotation of a rod guide and the sub-linear motion of the piston rod. When an injection amount of drug is preset through an injection amount setting module configured to make a rotational motion with a dose dial in a housing to set the amount of drug to be injected by storing the twisting moment in a torsion spring, a button plate is fixed and positioned in the dose dial to perform a function of supporting a button spring, and an injection button is slidably coupled through the button plate, so the injection button rotates simultaneously with the rotation of the dose dial, but allows a stable pushing operation through the button plate.

Abstract: A drug injection control device includes a housing, a dose dial rotatably coupled to the housing, a cartridge holder coupled to an opposite side of the housing, an injection button, a spring base non-rotatably coupled to the housing, an injection amount setting module to set an amount of the drug to be injected by storing a twisting moment in a torsion spring in the housing, and a drug delivery module to deliver a drug from the cartridge embedded in the cartridge holder by moving through the release of the twisting moment. The spring base includes a ratchet to engage with ratchet protrusions in the dose dial during the rotation of the dose dial, and feedback on the set injection amount of the drug is provided through generating a sound by sequential contact between the ratchet and the ratchet protrusions radially formed along a radial direction on the dose dial.